16 November 2018Big Pharma

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

Supplementary protection certificates (SPCs) are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

LSPN Europe 2018: Russian litigation and US second medical use

20 November 2018 The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.

Big Pharma

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

Big Pharma

SPC waiver proposal could discourage innovation, says pharma group

9 August 2018 A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

More on this story

Editor's picks

Editor's picks

More features